Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753–67. https://doi.org/10.1182/blood.2021013626

Article  CAS  PubMed  PubMed Central  Google Scholar 

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo C, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. https://doi.org/10.1182/blood.2022016867

Article  CAS  PubMed  Google Scholar 

Levis MJ, Hamadani M, Logan B, Jones R, Singh A, Litzow M, et al. Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol. 2024;42:1766–75. https://doi.org/10.1200/JCO.23.02474

Article  CAS  PubMed  Google Scholar 

Dillon LW, Gui G, Page KM, Ravindra N, Wong Z, Andrew G, et al. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA. 2023;329:745–55. https://doi.org/10.1001/jama.2023.1363

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hourigan CS, Dillon LW, Gui G, Logan B, Fei M, Ghannam J, et al. Impact of Conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020. https://doi.org/10.1200/JCO.19.03011

Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Socie G, Ljungman P, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018;93:1142–52. https://doi.org/10.1002/ajh.25211

Article  PubMed  Google Scholar 

Blackmon AL, Hourigan CS. Test then erase? Current status and future opportunities for measurable residual disease testing in acute myeloid leukemia. Acta Haematol. 2024;147:133–46. https://doi.org/10.1159/000535463

Article  CAS  PubMed  Google Scholar 

Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–31. https://doi.org/10.1182/blood-2017-08-798322

Article  CAS  PubMed  PubMed Central  Google Scholar 

Litzow MR, Sun Z, Mattison RJ, Paietta E, Roberts K, Zhang Y, et al. Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults. N Engl J Med. 2024;391:320–33. https://doi.org/10.1056/NEJMoa2312948

Article  CAS  PubMed  Google Scholar 

Stahl M, Derkach A, Farnoud N, Bewersdorf JP, Robinson T, Famulare C, et al. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. Am J Hematol. 2023;98:79–89. https://doi.org/10.1002/ajh.26757

Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021;5:1552–64. https://doi.org/10.1182/bloodadvances.2020003734

myeloMATCH Overview SWOG. Accessed October 21, 2024. https://www.swog.org/myelomatch-overview

Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Schulz J, et al. Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation. Blood Cancer J. 2021;11:1–4. https://doi.org/10.1038/s41408-021-00471-x

Article  Google Scholar 

Borlenghi E, Farina M, Chiarini M, Giustini V, Lamorgese C, Passi A, et al. The detection of minimal residual disease by multiparameter flow cytometry predicts a higher risk of relapse in patients with ELN intermediate-risk acute myeloid leukemia where molecular markers are not available. Blood. 2016;128:2882. https://doi.org/10.1182/blood.V128.22.2882.2882

Article  Google Scholar 

Chiarini M, Giustini V, Buccisano F, Borlenghi E, Farina M, Cattaneo C, et al. Identification of relapse risk using a multiparameter flow cytometry-based detection of minimal residual disease in adult patients with acute myeloid leukemia at ELN intermediate-risk. Blood. 2017;130:2697. https://doi.org/10.1182/blood.V130.Suppl_1.2697.2697

Article  Google Scholar 

Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012;120: 905–13. https://doi.org/10.1182/blood-2012-03-418202